License

Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets

July 30, 2020July 30, 2020Shiwani Sharma

Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M [Read More...]

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

BMS Signs an Exclusive Option to License Agreement with Dragonfly Therapeutics to Develop Novel Therapies for Multiple Sclerosis and Neuro-inflammation Targets

July 7, 2020July 7, 2020Shiwani Sharma

Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to [Read More...]

Sarepta Signs an Exclusive Worldwide License with Hansa to Develop Imlifidase for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophy

July 3, 2020July 3, 2020Tuba Khan

Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy [Read More...]

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Takeda Signs an Exclusive License and Research Agreement with Debiopharm to Develop Novel Microbiome Therapeutics for the Gastrointestinal Disorders

June 10, 2020June 10, 2020Tuba Khan

Shots: Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and [Read More...]